Form 4: Moderna CFO's Routine Stock Transactions Detailed in Latest SEC Form 4 Filing
Insider Transaction Report
Moderna's Chief Financial Officer, James M. Mock, reported the conversion of restricted stock units into common stock and subsequent sale of shares to cover tax obligations, as detailed in a recent Form 4 filing.
Summary
- James M. Mock, Moderna's Chief Financial Officer, reported transactions on July 3, 2025, involving Moderna, Inc. common stock and restricted stock units.
- Acquired 1,453 shares of Moderna Common Stock through the conversion of Restricted Stock Units (RSUs) on a one-for-one basis.
- Disposed of 703 shares of Common Stock at a price of $30.28 per share to satisfy tax withholding obligations in connection with the vesting of restricted stock units.
- Following these transactions, Mock beneficially owns 16,941 shares of Common Stock directly.
- Mock also beneficially owns 7,264 Restricted Stock Units directly after the reported transactions.
- The restricted stock unit award's vesting schedule commenced with 25% vesting on October 5, 2023, with the remaining portion vesting in twelve equal quarterly installments thereafter.
Sentiment
Score: 5
Explanation: The filing details routine insider transactions related to the vesting of restricted stock units and subsequent tax-related share dispositions, which are standard compensation practices and do not inherently indicate positive or negative company performance or outlook.
Positives
- The vesting of restricted stock units indicates continued long-term incentive alignment between the Chief Financial Officer and shareholder interests.
Negatives
- Disposition of 703 shares of common stock, even for tax withholding purposes, reduces the Chief Financial Officer's direct equity ownership.
Risks
- NA
Future Outlook
NA
Management Comments
- NA
Industry Context
This Form 4 filing is a routine disclosure of an insider's stock transactions and does not provide broader industry context or trends.
Comparison to Industry Standards
- NA
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
Legal Proceedings
- NA
Related Party Transactions
- NA
Stakeholder Impact
- Shareholders: Provides transparency on executive stock ownership and compensation practices.
- Employees: Reflects standard executive compensation structures involving equity awards.
Next Steps
- Remaining restricted stock units will continue to vest in twelve equal quarterly installments following October 5, 2023.
Key Dates
| Date | Description |
|---|---|
| 10/05/2023 | Initial vesting date for 25% of the restricted stock unit award. |
| 07/03/2025 | Date of reported transactions, including RSU conversion and share disposition. |
| 07/07/2025 | Date the Form 4 was signed by the Attorney-in-Fact. |
Keywords
Moderna, MRNA, SEC Form 4, insider transaction, stock ownership, Chief Financial Officer, James M. Mock, restricted stock units, RSU vesting, tax withholding
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.